Mode
Text Size
Log in / Sign up

Oral quadruple therapy reduces HbA more than metformin uptitration in type 2 diabetes on triple therapyWhen three diabetes pills aren't enough, does adding a fourth help more than increasing metformin?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider oral quadruple therapy as an option for intensification when metformin-based triple therapy is insufficient.

This 24-week, multicenter, open-label randomized controlled trial evaluated 193 adults with type 2 diabetes whose HbA remained between 7.0% and 9.0% despite treatment with metformin plus two other oral agents (a TZD, SGLT2i, or DPP-4i). Participants were randomized to either add a fourth oral agent from the class not previously used (oral quadruple therapy) or to uptitrate their metformin dose by up to 500 mg per day.

The primary outcome was change in HbA at week 24. The median HbA decrease was 0.70% (IQR 0.40%, 1.10%) in the quadruple therapy group versus 0.40% (IQR 0.10%, 0.80%) in the metformin uptitration group (p=0.002). A significantly higher proportion of patients achieved an HbA of ≤7.0% with quadruple therapy (69.7% vs 47.9%, p=0.006). The study reported improvements in insulin resistance and reductions in albuminuria in the quadruple group, but did not provide quantitative effect sizes for these outcomes.

Adverse events were described as mild and comparable between the two groups, though specific event rates, serious adverse events, and discontinuation data were not reported. A key limitation is the open-label trial design, which may introduce bias. The effect sizes for secondary metabolic and renal parameters were not quantified. These results support oral quadruple therapy as a potential intensification strategy, but the evidence is preliminary given the short 24-week duration and lack of detailed safety reporting.

Imagine taking three different pills for your diabetes, but your blood sugar still isn't where it needs to be. What's the next step? A new study tested two common choices: adding a fourth type of oral medication versus just increasing the dose of the metformin you're already on.

The trial involved 193 adults whose blood sugar (measured by HbA1c) was still too high despite being on three different diabetes pills. After 24 weeks, the group that got a fourth pill saw a greater drop in their HbA1c. Nearly 70% of them reached the target blood sugar level, compared to about 48% in the group that just got more metformin. The four-drug approach also showed signs of improving how the body uses insulin and reducing a marker of kidney stress, though the exact size of these benefits wasn't measured.

Importantly, side effects were described as mild and similar between the two groups. However, this was an open-label study, meaning everyone knew which treatment they were getting, which can sometimes influence results. We also don't know the specific safety event rates or what happened after the 24-week study period ended. The findings support the idea of a four-pill strategy as a potential next move, but more research is needed to understand the long-term picture.

What this means for you:
Adding a fourth diabetes pill beat a higher metformin dose for blood sugar control in a 24-week study.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up5.5 mo
PublishedApr 2026
View Original Abstract ↓
AIMS: To evaluate the efficacy and safety of adding a fourth oral antidiabetic drug versus metformin uptitration in patients with type 2 diabetes inadequately controlled with oral triple therapy. MATERIALS AND METHODS: In this 24-week, randomized, open-label trial, adults with type 2 diabetes having glycated haemoglobin (HbA) 7.0-9.0% despite oral triple therapy with metformin plus a thiazolidinedione (TZD), sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase 4 inhibitor (DPP-4i) were randomized to an oral quadruple add-on group or a metformin uptitration group. The quadruple group received the class not previously used (TZD, SGLT2i, or DPP-4i), whereas the metformin uptitration group increased the metformin dose by up to 500 mg per day. The primary endpoint was the change in HbA at week 24. Secondary endpoints included fasting glucose, metabolic parameters, and safety. RESULTS: Hundred and ninety-three were evaluable: 48 in the metformin uptitration group and 145 in the quadruple group. Compared to baseline, HbA at week 24 decreased by 0.70% (interquartile range [IQR] 0.40%, 1.10%) with quadruple therapy and 0.40% (IQR 0.10%, 0.80%) with metformin uptitration (p = 0.002). The rate achieving HbA ≤7.0% was higher in the quadruple group (69.7% vs. 47.9%, p = 0.006). Insulin resistance improved only in the quadruple group and was accompanied by reduced albuminuria. Adverse events were mild and comparable between groups. CONCLUSIONS: Oral quadruple therapy achieved greater glycaemic and metabolic improvement without compromising safety, compared with metformin uptitration, supporting its role as an intensification strategy.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.